Scribe Therapeutics Inc. (SCTX) Balance Sheet
SCTX balance sheet, 2025
December 31, 2025 · U.S. dollars$78.2M assets = $221.6M liabilities + −$143.4M equity
Liabilities exceed assets: shareholders’ equity is negative (−$143.4M).
Both columns are drawn to the same scale: what SCTX owns equals what it owes plus shareholders’ equity. Hover a block for its value.
SCTX financial health
Descriptive bands, not a rating. Fiscal 2025.
SCTX balance sheet trends, 2024–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $128.0M2024 | $78.2M2025 | −38.9%/yr | |
| Total liabilities | $253.8M2024 | $221.6M2025 | −12.7%/yr | |
| Shareholders’ equity | −$125.9M2024 | −$143.4M2025 | — | |
| Cash & short-term investments | $105.2M2024 | $58.0M2025 | −44.9%/yr | |
| Working capital | $75.4M2024 | −$2.1M2025 | −$77.5M | |
| Book value per share | −$7.162024 | −$8.162025 | — | |
| Current ratio | 3.152024 | 0.972025 | −2.18 | |
| Shares outstanding | 17.6M2024 | 17.6M2025 | 0.0%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
SCTX assets
SCTX liabilities and equity
SCTX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
SCTX balance sheet
| 2025 | 2024 | |
|---|---|---|
| Assets | ||
| Cash & short-term investments | $58.0M | $105.2M |
| Cash & equivalents | $12.8M | $12.6M |
| Short-term investments | $45.2M | $92.6M |
| Receivables | $0 | $0 |
| Inventory | $0 | $0 |
| Other current assets | $9.0M | $5.2M |
| Total current assets | $66.9M | $110.4M |
| Property, plant & equipment (net) | $10.1M | $13.2M |
| Goodwill & intangible assets | $0 | $0 |
| Long-term investments | $0 | $0 |
| Other non-current assets | $1.2M | $4.4M |
| Total assets | $78.2M | $128.0M |
| Liabilities | ||
| Accounts payable | $4.6M | $3.8M |
| Total current liabilities | $69.1M | $35.0M |
| Long-term debt | $0 | $34.5M |
| Lease obligations | $6.1M | $7.2M |
| Other long-term liabilities | $152.6M | $184.3M |
| Total liabilities | $221.6M | $253.8M |
| Shareholders' equity | ||
| Retained earnings (deficit) | −$157.7M | −$135.9M |
| Total shareholders' equity | −$143.4M | −$125.9M |
| Key figures | ||
| Total debt | — | $34.5M |
| Net cash (debt) | — | $70.7M |
| Working capital | −$2.1M | $75.4M |
| Tangible book value | −$143.4M | −$125.9M |
| Book value per share | −$8.16 | −$7.16 |
| Shares outstanding | 17.6M | 17.6M |
| Current ratio | 0.97 | 3.15 |
| Quick ratio | 0.84 | 3.00 |
| Equity / assets | −183.4% | −98.3% |
| Jun '26 | Mar '26 | |
|---|---|---|
| Assets | ||
| Cash & short-term investments | $43.0M | $49.7M |
| Cash & equivalents | $35.6M | $20.4M |
| Short-term investments | $7.4M | $29.4M |
| Receivables | $0 | $0 |
| Inventory | $0 | $0 |
| Other current assets | $2.1M | $2.7M |
| Total current assets | $45.1M | $52.4M |
| Property, plant & equipment (net) | $8.5M | $9.3M |
| Goodwill & intangible assets | $0 | $0 |
| Long-term investments | $0 | $0 |
| Other non-current assets | $4.3M | $3.5M |
| Total assets | $57.9M | $65.2M |
| Liabilities | ||
| Accounts payable | $2.8M | $5.1M |
| Total current liabilities | $78.7M | $79.7M |
| Long-term debt | $0 | $0 |
| Lease obligations | $5.5M | $5.8M |
| Other long-term liabilities | $144.1M | $144.2M |
| Total liabilities | $222.8M | $223.9M |
| Shareholders' equity | ||
| Retained earnings (deficit) | −$181.5M | −$175.1M |
| Total shareholders' equity | −$164.8M | −$158.7M |
| Key figures | ||
| Working capital | −$33.6M | −$27.3M |
| Tangible book value | −$164.8M | −$158.7M |
| Book value per share | −$9.38 | −$9.03 |
| Shares outstanding | 17.6M | 17.6M |
| Current ratio | 0.57 | 0.66 |
| Quick ratio | 0.55 | 0.62 |
| Equity / assets | −284.6% | −243.4% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed —); data from EODHD.
SCTX financial position
At the end of fiscal 2025 (December 31, 2025), Scribe Therapeutics had total assets of $78.2 million (down 38.9% from a year earlier), total liabilities of $221.6 million and shareholders' equity of -$143.4 million. Its current ratio was 0.97. In the latest quarter (ended June 30, 2026) total assets were $57.9 million and equity -$164.8 million.
Related: SCTX income statement, SCTX cash flow statement, SCTX key metrics. See the SCTX stock overview for the latest quote and news.
SCTX balance sheet FAQ
What are Scribe Therapeutics's total assets?
Scribe Therapeutics reported total assets of $78.2 million at the end of fiscal 2025 (December 31, 2025), compared with $128.0 million a year earlier.
How much cash does Scribe Therapeutics have?
Scribe Therapeutics held $58.0 million in cash and short-term investments at the end of fiscal 2025.
What is Scribe Therapeutics's book value?
Scribe Therapeutics's shareholders' equity (book value) was -$143.4 million at the end of fiscal 2025, or −$8.16 per share.
What is Scribe Therapeutics's current ratio?
Scribe Therapeutics had current assets of $66.9 million and current liabilities of $69.1 million, a current ratio of 0.97 (current liabilities exceed current assets).